BioCryst Pharmaceuticals Statistics
Share Statistics
BioCryst Pharmaceuticals has 207.13M shares outstanding. The number of shares has increased by 1.01% in one year.
| Shares Outstanding | 207.13M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.25% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 189.02M |
| Failed to Deliver (FTD) Shares | 3.63K |
| FTD / Avg. Volume | 0.18% |
Short Selling Information
The latest short interest is 20.83M, so 10.06% of the outstanding shares have been sold short.
| Short Interest | 20.83M |
| Short % of Shares Out | 10.06% |
| Short % of Float | 10.62% |
| Short Ratio (days to cover) | 13.03 |
Valuation Ratios
The PE ratio is -5.08 and the forward PE ratio is -195.5.
| PE Ratio | -5.08 |
| Forward PE | -195.5 |
| PS Ratio | 3.47 |
| Forward PS | 3 |
| PB Ratio | -2.53 |
| P/FCF Ratio | -11.83 |
| PEG Ratio | n/a |
Enterprise Valuation
BioCryst Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.89B.
| EV / Earnings | -8.33 |
| EV / Sales | 5.7 |
| EV / EBITDA | -16.22 |
| EV / EBIT | -18.2 |
| EV / FCF | -19.4 |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of -1.78.
| Current Ratio | 3.31 |
| Quick Ratio | 3.12 |
| Debt / Equity | -1.78 |
| Total Debt / Capitalization | 228.05 |
| Cash Flow / Debt | -0.12 |
| Interest Coverage | -0.96 |
Financial Efficiency
Return on equity (ROE) is 0.5% and return on capital (ROIC) is -26.41%.
| Return on Equity (ROE) | 0.5% |
| Return on Assets (ROA) | -0.44% |
| Return on Capital (ROIC) | -26.41% |
| Revenue Per Employee | 618.31K |
| Profits Per Employee | -422.65K |
| Employee Count | 536 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 0.16 |
Taxes
| Income Tax | 310.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 21.16% in the last 52 weeks. The beta is 1.89, so BioCryst Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.89 |
| 52-Week Price Change | 21.16% |
| 50-Day Moving Average | 7.61 |
| 200-Day Moving Average | 6.7 |
| Relative Strength Index (RSI) | 50.07 |
| Average Volume (20 Days) | 1.98M |
Income Statement
In the last 12 months, BioCryst Pharmaceuticals had revenue of $331.41M and earned -$226.54M in profits. Earnings per share was $-1.18.
| Revenue | 331.41M |
| Gross Profit | 326.75M |
| Operating Income | -103.71M |
| Net Income | -226.54M |
| EBITDA | -116.33M |
| EBIT | -103.71M |
| Earnings Per Share (EPS) | -1.18 |
Balance Sheet
The company has $110.64M in cash and $848.71M in debt, giving a net cash position of -$738.07M.
| Cash & Cash Equivalents | 110.64M |
| Total Debt | 848.71M |
| Net Cash | -738.07M |
| Retained Earnings | -1.68B |
| Total Assets | 491.25M |
| Working Capital | 273.56M |
Cash Flow
In the last 12 months, operating cash flow was -$95.14M and capital expenditures -$2.17M, giving a free cash flow of -$97.31M.
| Operating Cash Flow | -95.14M |
| Capital Expenditures | -2.17M |
| Free Cash Flow | -97.31M |
| FCF Per Share | -0.51 |
Margins
Gross margin is 98.59%, with operating and profit margins of -31.29% and -68.36%.
| Gross Margin | 98.59% |
| Operating Margin | -31.29% |
| Pretax Margin | -68.26% |
| Profit Margin | -68.36% |
| EBITDA Margin | -35.1% |
| EBIT Margin | -31.29% |
| FCF Margin | -29.36% |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -15.73% |
| FCF Yield | -6.26% |
Analyst Forecast
The average price target for BCRX is $12, which is 60% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 60% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -2.64 |
| Piotroski F-Score | 3 |